Prolonged response to combined BRAF and MEK inhibition in BRAF mutant colorectal cancer, a case report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Sustained Response to Combined BRAF and MEK Inhibition in Colorectal Cancer with BRAF Mutation: A Case Study

  • By

  • Michela Guardascione

  • Monica Rizzetto

  • Luisa Foltran

  • Paola Di Nardo

  • Marco de Scordilli

  • Elena Ongaro

  • Arianna Fumagalli

  • Anna Calabrò

  • Andrea Botticelli

  • Paolo Marchetti

  • Fabio Puglisi

  • July 16, 2026

Share

  • 1

    BRAF V600E-mutant metastatic colorectal cancer (BRAF mCRC) is linked to poor prognosis and limited durable responses.

  • 2

    The patient in the case study experienced a sustained response to vemurafenib and cobimetinib for nearly four years.

  • 3

    The combination of BRAF inhibitors and MEK inhibitors has shown potential efficacy in treating BRAF mCRC.

  • 4

    The case highlights the importance of personalized genomic profiling in treatment decision-making for BRAF mCRC.

  • 5

    This case represents the longest documented response to a MEKi-based regimen in BRAF mCRC, suggesting further investigation is warranted.

Original Source(s)

Prolonged response to combined BRAF and MEK inhibition in BRAF mutant colorectal cancer, a case report

  • by Michela Guardascione, Monica Rizzetto, Luisa Foltran, Paola Di Nardo, Marco de Scordilli, Elena Ongaro, Arianna Fumagalli, Anna Calabrò, Andrea Botticelli, Paolo Marchetti, Fabio Puglisi

  • July 16, 2026

Related Content

Matters arising in IJCD beyond minimally invasive pelvic exenteration: can single-port robotics overcome deep pelvic constraints?

Moving Cancer Survivorship Into Routine Care—Why Are We Still Not Ready for Change?

Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer

An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.

  • by

  • August 14, 2026

  • 6 min